Roche Holding AG ROA 2010-2024 | RHHBY

Current and historical return on assets (ROA) values for Roche Holding AG (RHHBY) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Roche Holding AG ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
Sector Industry Market Cap Revenue
Medical Large Cap Pharma $252.439B $68.726B
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) US $752.942B 57.71
Johnson & Johnson (JNJ) US $371.642B 15.37
AbbVie (ABBV) US $342.014B 18.83
Novo Nordisk (NVO) DK $294.382B 19.94
Novartis AG (NVS) CH $235.176B 13.43
Merck (MRK) US $209.962B 10.69
Sanofi (SNY) FR $136.671B 13.07
Pfizer (PFE) US $135.718B 7.45
Bayer (BAYRY) DE $25.425B 4.72
Innoviva (INVA) US $1.169B 10.78